Oragenics Inc. has completed the first site initiation visit for its Phase IIa clinical trial evaluating ONP-002 in Australia, formally launching clinical trial operations at the initial location. The milestone represents a significant step forward for the clinical-stage biotechnology company’s development of brain-targeted therapeutics using proprietary intranasal delivery technology.
The randomized, placebo-controlled study will enroll 40 patients presenting with acute concussion or mild traumatic brain injury, with the first dose administered within 12 hours of injury to evaluate safety, tolerability and preliminary clinical signals. The remaining two trial sites are currently completing Research Governance Office reviews following earlier Human Research Ethics Committee approval and are expected to activate soon, positioning all three sites to begin patient enrollment and dosing in the near term.
ONP-002 represents a first-in-class intranasal neurosteroid in Phase IIa clinical development for the treatment of concussion and mild traumatic brain injury. These conditions affect an estimated 69 million people globally each year with no approved pharmacological treatment currently available. The company’s intranasal delivery platform is designed to enable rapid, non-invasive delivery of therapeutics directly to the brain by bypassing the blood-brain barrier, potentially offering a novel approach to treating neurological conditions.
The clinical trial’s focus on acute concussion treatment within 12 hours of injury addresses a critical window for therapeutic intervention. The company is exploring broadening its central nervous system pipeline strategy through both internal development and strategic business development initiatives. More information about the company’s research and development programs can be found at https://www.Oragenics.com.
The initiation of clinical operations in Australia follows the company’s announcement of the trial’s design and objectives. The trial represents a significant advancement in the field of traumatic brain injury treatment, where current management primarily focuses on symptom monitoring and supportive care rather than pharmacological intervention targeting the underlying neurological processes.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oragenics Initiates First Clinical Site for Phase IIa Trial of Intranasal Concussion Treatment.